Jasper Therapeutics: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Jasper Therapeutics (NASDAQ:JSPR) reported its Q3 earnings, missing estimated earnings by 6.67% with an EPS of $-0.16 versus an estimate of $-0.15. Revenue was down $0 from the same period last year. Last quarter, the company also missed on EPS which was followed by a 1.42% drop in the share price the next day.
November 09, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jasper Therapeutics missed Q3 earnings estimates and reported a decrease in revenue. Last quarter's earnings miss led to a drop in share price.
Jasper Therapeutics missed its Q3 earnings estimates by 6.67%, reporting an EPS of $-0.16 versus an estimate of $-0.15. Additionally, the company's revenue was down from the same period last year. Given that the company's share price dropped by 1.42% the day after it missed earnings last quarter, it's reasonable to expect a similar reaction this time.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100